PDF(Pubmed)
Abstract：
Anti-SARS-CoV-2 vaccines were developed in response to the coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Although the BNT162b2 mRNA vaccine is effective, adverse effects have been reported. Here, we report a case of extranodal NK/T-cell lymphoma, nasal type (ENKL), of the left arm following BNT162b2 mRNA vaccination. A 73-year-old male presented with a lump in the left arm, which was the site where he received the BNT162b2 mRNA vaccine 3 months prior. He was treated with topical corticosteroids and debridement, but the tumor progressed. Additionally, fever, night sweats, and general fatigue were observed. Laboratory findings included thrombocytopenia, elevated lactate dehydrogenase, and soluble interleukin-2 receptor levels. Skin biopsy led to a diagnosis of ENKL. The patient was treated with a 50% dose of SMILE therapy and radiotherapy, resulting in regression of the tumor. It seems that latent Epstein-Barr virus (EBV)-infected NK/T cells were reactivated by vaccination and contributed to the onset of ENKL. This is the first report of ENKL after BNT162b2 mRNA vaccination. The present case highlights the possible risk of development of malignant lymphoma, including ENKL at the injection site, after BNT162b2 COVID-19 vaccination.
摘要：
抗SARS-CoV-2疫苗是针对由严重急性呼吸道综合症冠状病毒2（SARS-CoV-2）引起的2019年冠状病毒病（COVID-19）大流行而开发的。尽管BNT162b2mRNA疫苗是有效的，已经报道了不良反应。这里,我们报道一例结外NK/T细胞淋巴瘤,鼻型（ENKL），BNT162b2mRNA疫苗接种后的左臂。一名73岁的男性左臂有肿块，这是他3个月前接受BNT162b2mRNA疫苗的地方。他接受了局部皮质类固醇和清创术治疗，但肿瘤进展了.此外,发烧,盗汗,观察到一般疲劳。实验室检查结果包括血小板减少症，乳酸脱氢酶升高，和可溶性白细胞介素-2受体水平。皮肤活检导致ENKL的诊断。患者接受了50％剂量的SMILE治疗和放疗，导致肿瘤消退。似乎潜伏的爱泼斯坦-巴尔病毒（EBV）感染的NK/T细胞被疫苗接种重新激活，并有助于ENKL的发作。这是ENKL在BNT162b2mRNA接种后的首次报道。本案突出了恶性淋巴瘤发展的可能风险，包括注射部位的ENKL,BNT162b2COVID-19疫苗接种后。
